Reverse myocardial remodeling according to cardiac magnetic resonance imaging in patients with heart failure and atrial fibrillation receiving dapagliflozin

QR Code

Reverse myocardial remodeling according to cardiac magnetic resonance imaging in patients with heart failure and atrial fibrillation receiving dapagliflozin

Aim. To determine the effect of dapagliflozin on cardiac remodeling parameters and left ventricular mass according to cardiac magnetic resonance imaging in patients with heart failure (HF) with reduced ejection fraction (EF) and atrial fibrillation (AF).Material and methods. The study included 60 pa...

Full description

Saved in:

Bibliographic Details
Main Authors:	K. M. Saipudinova, T. M. Uskach, M. A. Sharia, D. V. Ustyuzhanin, S. N. Tereshchenko
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2024-10-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	heart failure atrial fibrillation cardiac magnetic resonance imaging left ventricular mass sodium-glucose cotransporter type 2 inhibitors
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/4090
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction—DAPA-STEMI Trial
by: Luis Ortega-Paz, et al.
Published: (2025-06-01)

Euglycemic diabetic ketoacidosis and a probable Fanconi syndrome secondary to dapagliflozin: a case report
by: Luis E. Fernández-Garza, et al.
Published: (2025-07-01)

SGLT2 inhibitor administration to two patients with diabetes mellitus with ascites due to cirrhosis
by: Koji Nagayama, et al.
Published: (2025-07-01)

Management of Patients with Chronic Heart Failure and Diabetes Mellitus
by: E. V. Reznik, et al.
Published: (2021-05-01)

Acute kidney injury as a risk factor for atrial fibrillation after coronary artery bypass grafting — effects of sodium-glucose cotransporter-2 inhibitors
by: L. V. Kremneva, et al.
Published: (2023-12-01)

Antifibrotic effects of sodium-glucose cotransporter 2 inhibitors in patients with heart failure
by: Yu. S. Ignatova, et al.
Published: (2024-02-01)

Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
by: N. B. Perepech, et al.
Published: (2021-07-01)

Liver function effects of SGLT2 inhibitor and GLP‐1 receptor agonist combination treatment in patients with type 2 diabetes (post hoc analysis of RECAP study)
by: Daisuke Tsuriya, et al.
Published: (2025-07-01)

Induction of proximal tubular proliferation and lengthening in response to sodium glucose linked cotransporter‐2 inhibition in experimental rats
by: Ellen Wu, et al.
Published: (2025-07-01)

HYPERTHYROIDISM AND ATRIAL FIBRILLATION
by: I. M. Marusenko, et al.
Published: (2017-07-01)

SGLT2 inhibitors in lupus nephritis: a multicentric study in Latin America
by: José L. Daza, et al.
Published: (2025-04-01)

"<i>Primum non nocere</i> (First, do no harm)". Case report
by: D. A. Nefedova, et al.
Published: (2023-06-01)

NLRP3 Inflammasome — a new universal target of asymptomatic hyperuricemia and gout management
by: P. A. Lebedev, et al.
Published: (2024-07-01)

Targeting ion channel networks in diabetic kidney disease: from molecular crosstalk to precision therapeutics and clinical innovation
by: Wenfeng Wang, et al.
Published: (2025-06-01)

Patterns of structural and functional remodeling of the left ventricle in patients with various forms of atrial fibrillation
by: A. I. Kochetkov, et al.
Published: (2024-04-01)

Special aspects of remodeling of the left ventricle in hypertensive disease
by: Mariya V. Ozhereleva, et al.
Published: (2017-12-01)

Differential Effects of SGLT-2 Inhibitors on Liver Function and Nocturia in Patients with Type 2 Diabetes: A Randomized Controlled Trial
by: Kawahara T, et al.
Published: (2025-07-01)

Management of comorbid patients with chronic kidney disease and decline in renal function: a case report
by: A. I. Listratov, et al.
Published: (2024-10-01)

Changes of natriuresis and prediction of cardiovascular events in patients with type 2 diabetes and decompensated heart failure over therapy with sodium-glucose cotransporter 2 inhibitors and standard diuretic therapy
by: O. A. Abdullaev, et al.
Published: (2024-03-01)

Refractory Arterial Hypertension: Features of Neurohormonal and Water-salt Imbalanceand Approaches to Antihypertensive Drug Therapy
by: O. B. Kuzmin, et al.
Published: (2022-09-01)

Left Atrial Remodeling Identification and Catheter Ablation Outcomes With 18F‐Fluorodeoxyglucose Positron Emission Tomography in Persistent Atrial Fibrillation
by: Tristan Raoult, et al.
Published: (2025-07-01)

Overweight and early heart remodelling in women with arterial hypertension
by: E. M. Khurs, et al.
Published: (2010-04-01)

Echocardiographic effects of sodium-glucose cotransporter 2 inhibitors in single ventricle circulatory failure
by: Ralph M.L. Neijenhuis, et al.
Published: (2025-09-01)

New opportunities for the correction of type 2 diabetes mellitus in patients with liver diseases
by: L. Yu. Morgunov, et al.
Published: (2022-01-01)

Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Post-Transurethral Resection of Bladder Tumor Infection and Prognosis
by: Nobutaka Nishimura, et al.
Published: (2025-07-01)

Empagliflozin: a path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations
by: N. R. Khasanov
Published: (2022-02-01)

Implantation of a cardiac contractility modulator in chronic heart failure and atrial fibrillation: results of a 6-month follow-up of one hundred patients
by: T. M. Uskach, et al.
Published: (2021-04-01)

Left ventricular remodelling early after surgical correction of mitral regurgitation: stroke volume maintenance
by: E. A. Ashikhmina, et al.
Published: (2013-02-01)

Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
by: Qin Li, et al.
Published: (2025-07-01)

ANTIARRHYTHMIC THERAPY EFFECTIVENESS AND IMPACT ON LEFT VENTRICULAR DIASTOLIC FUNCTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: O. N. Miller, et al.
Published: (2011-08-01)

Sodium-Dependent Glucose Transporter Type 2 Inhibitors as a Breakthrough in Neutropenia and Neutrophil Dysfunction Management in Patients with Glycogen Storage Disease Type Ib
by: Andrey N. Surkov, et al.
Published: (2024-07-01)

Sodium–glucose cotransporter 2 inhibitors ameliorate glutathione cysteine ligase modifier-mediated oxidative stress and subsequent ferroptosis in proximal tubules of diabetic kidney disease
by: Yi-Chun Tsai, et al.
Published: (2025-12-01)

Application of SGLT-2 inhibitors in non-diabetic CKD: mechanisms, efficacy, and safety
by: Bing Zhang, et al.
Published: (2025-07-01)

In search of heart barometer—advantage of left atrial dimension over electrocardiographic indices of left ventricular hypertrophy in arterial hypertension
by: Bogusława Nowak, et al.
Published: (2023-07-01)

Arterial stiffness as a factor of structural and functional cardiac remodeling in obesity
by: M. A. Druzhilov, et al.
Published: (2020-06-01)

Reverse remodeling against the background of cardiac contractility modulation therapy in patients with heart failure and atrial fibrillation
by: A. A. Safiullina, et al.
Published: (2022-02-01)

Assessment of LV structural remodelling by the application of the finite element method to 3D echocardiography data
by: Yongjae Lee, et al.
Published: (2024-12-01)

Predictive factors of early left ventricular remodeling and reverse remodeling in patients with STEMI after successful reperfusion therapy
by: Yanbo Wang, et al.
Published: (2025-09-01)

Antiarrhythmic therapy choice in patients with left ventricular diastolic dysfunction and atrial fibrillation
by: A. V. Tarasov, et al.
Published: (1970-01-01)

Early left ventricular remodelling criteria and antihypertensive therapy effectiveness
by: L. L. Kirichenko, et al.
Published: (2011-06-01)